4 clinical trials, market cap 158 million. If that strikes you as crazy, given that the clinical trials are for a novel class of antibiotic that probably won't allow resistant bacteria to develop, a treatment for 50% of cancers, a treatment or cure of psoriasis, a treatment for chemo/radiation-induced mouth ulcers that currently have no treatment, and then the projected ulcerative proctitis clinical trial -- then this is the time to buy more.

I am doing so.